Adjuvare Launches Real-Time Remote Patient Monitoring Combining AI Mobile Technology and Virtual Acute-Care Services – Yahoo Finance

Powered by AirStrip ONE®’s Intelligent Clinical Operating Environment in use at over 500 Hospitals
Advance platform revolutionizes on-site and remote real-time patient and therapeutic monitoring
SAN ANTONIO & SAN DIEGO, November 29, 2021–(BUSINESS WIRE)–AirStrip, the leader in innovative visualization technology for acute care clinicians, today announced the formation and integration of its platform with Adjuvare, Inc. The creation of the inter-operative and AI augmented Adjuvare platform will extend acute and semi-acute patient care from the hospital to the patient’s home with the establishing of the "NORAD" of Virtual Acute Care.
Adjuvare, funded by NantWorks, is built atop the AirStrip ONE® Intelligent Clinical Operating Environment, a virtual care inter-operable system that is already in use by more than 500 hospitals and embedded in existing solutions from strategic technology partners. The company’s mission is to revolutionize on-site and remote patient and therapeutic monitoring by enabling video and mobile based, real time continuum of acute care, from the hospital to the home. The company was founded by NantWorks founder and Chairman Dr. Patrick Soon-Shiong, M.D., and is led by Alan Portela, AirStrip’s CEO.
The new platform solves the ongoing real-time monitoring challenges that arise in a Virtual Acute Care setting, starting with the hospital and following patients needing acute and semi-acute care into the home. Adjuvare combines AirStrip’s proven advanced virtual care technology and virtual acute care services in a single data-driven, patient-centric and clinical disease-oriented system, powered by AI enabled ECG monitoring. This addresses a range of technological, security, scale, and real-time monitoring challenges, using AI innovations from NantWorks combined with AirStrip’s comprehensive medical data interoperability, security, analytics, and mobile visualization and video consulting capabilities.
"We have had the privilege of collaborating with AirStrip’s healthcare provider customers, who taught us the lessons learned from the front lines during the pandemic," said Portela. "That level of unprecedented collaboration, which was complemented by the NantWorks Machine Learning team, translated into the development of the most advanced AI-augmented Disease surveillance tools, virtual acute care clinical services and therapies. These are now going to be offered by Adjuvare and are expected to transform patient virtual care for decades to come."
Adjuvare, supported by NantWorks, will be used for the creation of a Virtual Acute Care Remote Monitoring and Clinical Services division which will be augmented by partnering with a large group of Acute Care Physicians including ER doctors, hospitalists, specialists, nurses, pharmacists and other clinical extenders.
Adjuvare will also create a Human Signal Processing Division to continue its deep collaboration with top healthcare provider partners for the development of advanced Patient Waveform Analysis (AI/ML) designed for early detection and prediction of adverse clinical events. It also envisions establishing a high performance and cybersecure network infrastructure division to bring high velocity analytics and archiving of clinically relevant data in motion. This new model of Virtual Mission Control Surveillance will transform the cost of this patient group and drive better outcomes through real-time monitoring, timely access to specialist care and AI- augmented surveillance solutions.
"It has been a long-held dream to drive real-time cognition to the critical and chronic care model which drives the high cost of healthcare," Soon-Shiong said. "Adjuvare, powered by the advanced wave form analytic tools of Airstrip combined with a secure network infrastructure, integrated with specialists who bring evidence based just-in time care and better outcomes, brings this dream to fruition."
About AirStrip
AirStrip ONE® offers solutions that allow hundreds of health systems to unlock the full potential of their existing medical technology infrastructure investments with an interoperability platform that provides seamless access to clinical data and mobile actionable insights across the care continuum using remote access or web access granted by the health system. It features mobile diagnostic quality cardiac waveform viewing and sophisticated mobile fetal surveillance, providing clinicians with near-real-time contextual and clinically relevant data for situational awareness.
For more information visit,
View source version on
Jen Hodson
[email protected]
In the presence of Canada's Transport Minister, the Honorable Omar Alghabra, VIA Rail's Chairperson of the Board, Françoise Bertrand, and President and CEO Cynthia Garneau invite you to get a first look at our new test train, the first of 32 trainsets to be delivered to VIA Rail to replace its fleet in the Quebec City-Windsor corridor.
We can readily understand why investors are attracted to unprofitable companies. For example, although…
Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant. Inc's cloud computing unit on Tuesday introduced two new custom computing chips aimed at helping its customers beat the cost of using chips from Intel Corp and Nvidia Corp. With $45.37 billion in sales in 2020, Amazon Web Services (AWS) is the world's biggest cloud computing provider and one of the biggest buyers of data center chips, whose computing power AWS rents out to its customers. Ever since buying a startup called Annapurna Labs in 2015, AWS has worked to develop its own custom chips.
Adagio Therapeutics Inc. is riding high after the company said its experimental antibody is likely to be just as effective against the omicron variant of the coronavirus as it is against previous variants. The antibody, a drug called ADG20, affords protection for up to one year, according to the firm.
The Malvern firm has a deal that will get it 45% of sales of the Covid-19 vaccine in the United States, if the product gets FDA approval.
Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. Indeed, headlines regarding the new omicron variant of the coronavirus began to surface before Thursday's Thanksgiving holiday. It just took a while for investors to connect the dots all the way back to Vir Biotechnology, which potentially benefits from a renewed outbreak of infections stemming from this new strain of the pandemic-causing virus.
The rise of the new Omicron variant has indicated the pandemic is an ongoing concern, suggesting newcomers to the Covid-19 vaccine space could still have a significant role to play in battling the coronavirus. However, it looks like it might be a while still until late entrant Ocugen (OCGN) will be able to play its part. Last week, the company announced that its investigational new drug (IND) application for Covaxin – the Covid-19 vaccine the company has licensed from India-based Bharat Biotech
The New York Times reports more than 775,000 Americans have died from COVID-19 and more than 48 million have had the virus. However, many others have likely had COVID but weren't tested or were asymptomatic and didn't realize they had it. While it's impossible to know if you've been infected without seeing a physician or getting tested, there are signs you've had it. COVID affects everyone differently, but according to virus and medical experts Eat This, Not That! Health spoke with, here are the
Qualcomm Inc on Tuesday released its new top-tier smartphone chip aimed at premium-priced Android phones with features like sharper photos and graphics than handsets using chips from rivals. The San Diego, California-based company is the biggest supplier of the chips at the heart of many Android phones, competing against rivals such as Taiwan's MediaTek Inc and Samsung Electronics Co Ltd, which uses Qualcomm chips in some of its phones but self-supplies chips for some models.
Moderna CEO Stéphane Bancel said that based on his conversations with scientists, current vaccines will likely be less effective against the Omicron variant. Yahoo Finance's Ines Ferre provides details.
According to the charts, VEEV appears weak and prone to further declines ahead of earnings.
Year to date, the meme-based coin is up 63 million percent.
A survey finds the majority of U.S. employers will require employees to get COVID-19 vaccinations; few workers are quitting over the mandate.
Is Pfizer stock a buy after a new Covid variant emerged that could undo its Covid vaccine? Is PFE stock a buy right now?
The biotech company's monoclonal antibody is likely to be less effective against the new strain.
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discus the spread of the Omicron COVID-19 variant. 
As you dream, your brain sifts through your memories, thoughts, and feelings. And while most people are aware that dreams can serve as a window into our cognitive states, fewer realize that they can also shed light onto aspects of our physical health. Experts from the Sleep Cycle Center (SCC) say that in particular, your dreams may be able to alert you to a potentially dangerous disorder that occurs in sleep. That's because as your brain subconsciously processes your physical symptoms, it can co
The stock market saw its recent volatility continue on Tuesday morning, as ongoing concerns about longer-term impacts of new COVID-19 variants weighed on market sentiment. As of 11:30 a.m. ET, the Nasdaq Composite (NASDAQINDEX: ^IXIC) had given up early gains and was down 204 points to 15,579. Immunogen (NASDAQ: IMGN) and Molecular Technology (NASDAQ: MOLN) were big gainers on the Nasdaq Tuesday morning, and the news they announced could keep boosting their shares for some time to come.